公开(公告)号：US12098182B2

公开(公告)日：2024-09-24

申请号：US16575624

申请日：2019-09-19

Applicant: Regents of the University of Minnesota

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Ni

IPC: C12N15/63 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  C07K14/735 ,  C07K16/32 ,  C12N5/00 ,  C12N5/0783 ,  C12N5/0786 ,  C12N5/0787 ,  A61K39/00 ,  A61K48/00

CPC classification number: C07K14/70535 ,  A61K35/17 ,  A61K38/1774 ,  A61K39/39558 ,  C07K16/32 ,  C12N5/0642 ,  C12N5/0645 ,  C12N5/0646 ,  A61K2039/505 ,  C07K2317/76 ,  C12N2501/599 ,  C12N2510/00

Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

公开(公告)号：US20240124550A1

公开(公告)日：2024-04-18

申请号：US18474781

申请日：2023-09-26

Applicant: Regents of the University of Minnesota

Inventor： Jianming Wu ,  Bruce Kenneth Walcheck ,  Robert Harrison Hullsiek ,  Yungfang Li ,  Hemant Kumar Mishra

IPC: C07K14/735 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K14/70535 ,  C07K16/30 ,  C12N5/0646 ,  C07K2317/24 ,  C07K2319/74

Abstract: A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

公开(公告)号：US20240417441A1

公开(公告)日：2024-12-19

申请号：US18800744

申请日：2024-08-12

Applicant: Regents of the University of Minnesota

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Ni

IPC: C07K14/735 ,  A61K38/17 ,  A61K39/00 ,  A61K39/395 ,  C07K16/32 ,  C12N5/0783 ,  C12N5/0786 ,  C12N5/0787

Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

公开(公告)号：US11370825B2

公开(公告)日：2022-06-28

申请号：US17233979

申请日：2021-04-19

Applicant: Regents of the University of Minnesota

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Ni

IPC: C07H21/04 ,  C12N15/63 ,  C07K17/00 ,  A61K48/00 ,  C07K14/735 ,  C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  C07K16/32 ,  C12N5/0787 ,  C12N5/0786 ,  A01K67/00 ,  A61K39/00

Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

公开(公告)号：US20210332103A1

公开(公告)日：2021-10-28

申请号：US17233979

申请日：2021-04-19

Applicant: Regents of the University of Minnesota

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Ni

IPC: C07K14/735 ,  C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  C07K16/32 ,  C12N5/0787 ,  C12N5/0786

Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

公开(公告)号：US20200283501A1

公开(公告)日：2020-09-10

申请号：US16758142

申请日：2018-10-26

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Jianming Wu ,  Bruce Kenneth Walcheck ,  Robert Harrison Hullsiek ,  Yungfang Li ,  Hemant Kumar Mishra

IPC: C07K14/735 ,  C12N5/0783 ,  C07K16/30

Abstract: A recombinant immune cell expresses a heterologous IgG Fc receptor. In some embodiments, the heterologous IgG Fc receptor can be a chimeric IgG Fc receptor. Generally, the chimeric IgG Fc receptor includes an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain generally includes a sufficient portion of CD64 to bind to an IgG Fc region. The intracellular domain of the chimeric IgG Fc receptor includes a sufficient portion of an Fc receptor allowing immunoreceptor tyrosine-based activation motif (ITAM) to initiate cell signaling when an IgG Fc region binds to the extracellular domain.

公开(公告)号：US20200017570A1

公开(公告)日：2020-01-16

申请号：US16575624

申请日：2019-09-19

Applicant: Regents of the University of Minnesota

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Ni

IPC: C07K14/735 ,  C12N5/0786 ,  C12N5/0787 ,  C07K16/32 ,  A61K39/395 ,  A61K38/17 ,  A61K35/17 ,  C12N5/0783

Abstract: This disclosure describes, generally, a modified form of CD16, genetically-modified cells that express the modified CD16, and methods that involve the genetically-modified cells. The modified form of CD16 can exhibit increased anti-tumor and/or anti-viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

公开(公告)号：US10464989B2

公开(公告)日：2019-11-05

申请号：US15300024

申请日：2015-03-27

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Ni

IPC: A61K48/00 ,  C07H21/04 ,  C07K14/735 ,  C12N5/0783 ,  A61K35/17 ,  A61K38/17 ,  A61K39/395 ,  C07K16/32 ,  C12N5/0787 ,  C12N5/0786 ,  A01K67/00 ,  A61K39/00

Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

公开(公告)号：US20170174743A1

公开(公告)日：2017-06-22

申请号：US15300024

申请日：2015-03-27

Applicant: REGENTS OF THE UNIVERSITY OF MINNESOTA

Inventor： Bruce Kenneth Walcheck ,  Dan Samuel Kaufman ,  Jianming Wu ,  Yawu Jing ,  Zhenya Li

IPC: C07K14/735 ,  A61K38/17 ,  C12N5/0786 ,  A61K39/395 ,  C12N5/0783 ,  C12N5/0787 ,  A61K35/17 ,  C07K16/32

CPC classification number: C07K14/70535 ,  A61K35/17 ,  A61K38/1774 ,  A61K39/39558 ,  A61K2039/505 ,  C07K16/32 ,  C07K2317/76 ,  C12N5/0642 ,  C12N5/0645 ,  C12N5/0646 ,  C12N2501/599 ,  C12N2510/00

Abstract: This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.